Does the media refer more to RLAY or LXRX?

In the previous week, Relay Therapeutics had 14 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 16 mentions for Relay Therapeutics and 2 mentions for Lexicon Pharmaceuticals. Relay Therapeutics' average media sentiment score of 0.86 beat Lexicon Pharmaceuticals' score of 0.37 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Lexicon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, PBLS or LXRX?

Parabilis Medicines has higher earnings, but lower revenue than Lexicon Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Parabilis Medicines N/A N/A N/A N/A N/A Lexicon Pharmaceuticals $49.80M 19.48 -$50.34M -$0.15 N/A

Does the media prefer PBLS or LXRX?

In the previous week, Parabilis Medicines had 2 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 4 mentions for Parabilis Medicines and 2 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.37 beat Parabilis Medicines' score of 0.01 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Parabilis Medicines 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lexicon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to VKTX or LXRX?

In the previous week, Viking Therapeutics had 7 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 9 mentions for Viking Therapeutics and 2 mentions for Lexicon Pharmaceuticals. Viking Therapeutics' average media sentiment score of 0.90 beat Lexicon Pharmaceuticals' score of 0.37 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Lexicon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to DNLI or LXRX?

In the previous week, Denali Therapeutics had 4 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 6 mentions for Denali Therapeutics and 2 mentions for Lexicon Pharmaceuticals. Denali Therapeutics' average media sentiment score of 0.94 beat Lexicon Pharmaceuticals' score of 0.37 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexicon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TNGX or LXRX?

In the previous week, Tango Therapeutics had 17 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 19 mentions for Tango Therapeutics and 2 mentions for Lexicon Pharmaceuticals. Tango Therapeutics' average media sentiment score of 0.93 beat Lexicon Pharmaceuticals' score of 0.37 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexicon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Lexicon Pharmaceuticals (LXRX) Competitors

$2.18 -0.23 (-9.54%)

Closing price 04:00 PM Eastern

Extended Trading

$2.20 +0.02 (+0.92%)

As of 06:27 PM Eastern

Compare

LXRX vs. RLAY, PBLS, VKTX, DNLI, and TNGX

Should you buy Lexicon Pharmaceuticals stock or one of its competitors? Lexicon Pharmaceuticals's main competitors and comparable companies include Relay Therapeutics (RLAY), Parabilis Medicines (PBLS), Viking Therapeutics (VKTX), Denali Therapeutics (DNLI), and Tango Therapeutics (TNGX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lexicon Pharmaceuticals compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

In the previous week, Relay Therapeutics had 14 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 16 mentions for Relay Therapeutics and 2 mentions for Lexicon Pharmaceuticals. Relay Therapeutics' average media sentiment score of 0.86 beat Lexicon Pharmaceuticals' score of 0.37 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Relay Therapeutics currently has a consensus target price of $25.92, indicating a potential upside of 31.56%. Lexicon Pharmaceuticals has a consensus target price of $4.55, indicating a potential upside of 108.72%. Given Lexicon Pharmaceuticals' higher probable upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.86
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Lexicon Pharmaceuticals has higher revenue and earnings than Relay Therapeutics. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	281.24	-$276.48M	-$1.57	N/A
Lexicon Pharmaceuticals	$49.80M	19.48	-$50.34M	-$0.15	N/A

97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Relay Therapeutics has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

Relay Therapeutics has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -147.38%. Lexicon Pharmaceuticals' return on equity of -37.53% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-42.27%	-38.67%
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%

Summary

Relay Therapeutics beats Lexicon Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Parabilis Medicines?

Parabilis Medicines (NASDAQ:PBLS) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

In the previous week, Parabilis Medicines had 2 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 4 mentions for Parabilis Medicines and 2 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.37 beat Parabilis Medicines' score of 0.01 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Parabilis Medicines	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lexicon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Parabilis Medicines has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -147.38%. Parabilis Medicines' return on equity of 0.00% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Parabilis Medicines	N/A	N/A	N/A
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%

Parabilis Medicines currently has a consensus price target of $41.67, suggesting a potential upside of 5.27%. Lexicon Pharmaceuticals has a consensus price target of $4.55, suggesting a potential upside of 108.72%. Given Lexicon Pharmaceuticals' higher possible upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Parabilis Medicines	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Parabilis Medicines has higher earnings, but lower revenue than Lexicon Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A
Lexicon Pharmaceuticals	$49.80M	19.48	-$50.34M	-$0.15	N/A

Summary

Parabilis Medicines beats Lexicon Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by company insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Viking Therapeutics had 7 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 9 mentions for Viking Therapeutics and 2 mentions for Lexicon Pharmaceuticals. Viking Therapeutics' average media sentiment score of 0.90 beat Lexicon Pharmaceuticals' score of 0.37 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lexicon Pharmaceuticals has higher revenue and earnings than Viking Therapeutics. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
Lexicon Pharmaceuticals	$49.80M	19.48	-$50.34M	-$0.15	N/A

Viking Therapeutics has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -147.38%. Lexicon Pharmaceuticals' return on equity of -37.53% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%

Viking Therapeutics currently has a consensus price target of $96.63, suggesting a potential upside of 181.21%. Lexicon Pharmaceuticals has a consensus price target of $4.55, suggesting a potential upside of 108.72%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Viking Therapeutics is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Viking Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

Summary

Viking Therapeutics beats Lexicon Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

Lexicon Pharmaceuticals has lower revenue, but higher earnings than Denali Therapeutics. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	12.07	-$512.54M	-$2.84	N/A
Lexicon Pharmaceuticals	$49.80M	19.48	-$50.34M	-$0.15	N/A

Denali Therapeutics has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -147.38%. Lexicon Pharmaceuticals' return on equity of -37.53% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-55.27%	-44.24%
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 9.7% of Denali Therapeutics shares are owned by insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Denali Therapeutics presently has a consensus target price of $35.92, indicating a potential upside of 43.95%. Lexicon Pharmaceuticals has a consensus target price of $4.55, indicating a potential upside of 108.72%. Given Lexicon Pharmaceuticals' higher possible upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Denali Therapeutics had 4 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 6 mentions for Denali Therapeutics and 2 mentions for Lexicon Pharmaceuticals. Denali Therapeutics' average media sentiment score of 0.94 beat Lexicon Pharmaceuticals' score of 0.37 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Denali Therapeutics has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market.

Summary

Denali Therapeutics and Lexicon Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Tango Therapeutics currently has a consensus target price of $43.46, indicating a potential upside of 84.86%. Lexicon Pharmaceuticals has a consensus target price of $4.55, indicating a potential upside of 108.72%. Given Lexicon Pharmaceuticals' higher probable upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Tango Therapeutics had 17 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 19 mentions for Tango Therapeutics and 2 mentions for Lexicon Pharmaceuticals. Tango Therapeutics' average media sentiment score of 0.93 beat Lexicon Pharmaceuticals' score of 0.37 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lexicon Pharmaceuticals has lower revenue, but higher earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	63.55	-$101.59M	-$0.85	N/A
Lexicon Pharmaceuticals	$49.80M	19.48	-$50.34M	-$0.15	N/A

Tango Therapeutics has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

Tango Therapeutics has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -147.38%. Tango Therapeutics' return on equity of -25.75% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-25.75%	-23.36%
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%

Summary

Tango Therapeutics beats Lexicon Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Lexicon Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LXRX vs. The Competition

Export

Metric	Lexicon Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.07B	$4.07B	$7.37B	$12.86B
Dividend Yield	N/A	3.64%	2.53%	10.69%
P/E Ratio	-14.53	11.53	268.43	24.05
Price / Sales	19.48	1,311.61	610.34	88.11
Price / Cash	N/A	103.92	78.13	53.57
Price / Book	5.59	17.09	13.07	6.15
Net Income	-$50.34M	-$12.52M	$3.46B	$347.39M
7 Day Performance	-6.84%	2.74%	1.43%	-0.64%
1 Month Performance	-6.44%	6.15%	4.58%	2.12%
1 Year Performance	92.92%	60.36%	27.60%	20.16%

Lexicon Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LXRX Lexicon Pharmaceuticals	1.4325 of 5 stars	$2.18 -9.5%	$4.55 +108.7%	+107.8%	$1.07B	$49.80M	N/A	140
RLAY Relay Therapeutics	3.3224 of 5 stars	$19.94 +0.9%	$25.58 +28.3%	+510.0%	$4.33B	$15.35M	N/A	330	News Coverage Analyst Forecast
PBLS Parabilis Medicines	2.1129 of 5 stars	$35.73 +2.1%	$41.67 +16.6%	N/A	$4.13B	N/A	N/A	N/A	Earnings Report
VKTX Viking Therapeutics	3.363 of 5 stars	$34.44 +0.5%	$97.88 +184.2%	+47.7%	$4.00B	N/A	N/A	20	Positive News Analyst Upgrade
DNLI Denali Therapeutics	3.1257 of 5 stars	$25.00 +0.7%	$35.92 +43.7%	+73.5%	$3.94B	$330.53M	N/A	430	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LXRX) was last updated on 8/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lexicon Pharmaceuticals (LXRX) Competitors

LXRX vs. RLAY, PBLS, VKTX, DNLI, and TNGX

How does Lexicon Pharmaceuticals compare to Relay Therapeutics?

Summary

How does Lexicon Pharmaceuticals compare to Parabilis Medicines?

Summary

How does Lexicon Pharmaceuticals compare to Viking Therapeutics?

Summary

How does Lexicon Pharmaceuticals compare to Denali Therapeutics?

Summary

How does Lexicon Pharmaceuticals compare to Tango Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXRX vs. The Competition

Lexicon Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lexicon Pharmaceuticals (LXRX) Competitors

LXRX vs. RLAY, PBLS, VKTX, DNLI, and TNGX

How does Lexicon Pharmaceuticals compare to Relay Therapeutics?

Does the media refer more to RLAY or LXRX?

Do analysts recommend RLAY or LXRX?

Which has stronger earnings & valuation, RLAY or LXRX?

Do institutionals and insiders believe in RLAY or LXRX?

Which has more risk and volatility, RLAY or LXRX?

Is RLAY or LXRX more profitable?

Summary

How does Lexicon Pharmaceuticals compare to Parabilis Medicines?

Does the media prefer PBLS or LXRX?

Do insiders & institutionals hold more shares of PBLS or LXRX?

Is PBLS or LXRX more profitable?

Do analysts rate PBLS or LXRX?

Which has higher valuation and earnings, PBLS or LXRX?

Summary

How does Lexicon Pharmaceuticals compare to Viking Therapeutics?

Do institutionals & insiders believe in VKTX or LXRX?

Does the media refer more to VKTX or LXRX?

Which has preferable earnings & valuation, VKTX or LXRX?

Is VKTX or LXRX more profitable?

Do analysts prefer VKTX or LXRX?

Which has more volatility and risk, VKTX or LXRX?

Summary

How does Lexicon Pharmaceuticals compare to Denali Therapeutics?

Which has stronger valuation & earnings, DNLI or LXRX?

Is DNLI or LXRX more profitable?

Do insiders & institutionals believe in DNLI or LXRX?

Do analysts prefer DNLI or LXRX?

Does the media refer more to DNLI or LXRX?

Which has more risk & volatility, DNLI or LXRX?

Summary

How does Lexicon Pharmaceuticals compare to Tango Therapeutics?

Do analysts recommend TNGX or LXRX?

Do institutionals and insiders have more ownership in TNGX or LXRX?

Does the media refer more to TNGX or LXRX?

Which has stronger valuation & earnings, TNGX or LXRX?

Which has more volatility and risk, TNGX or LXRX?

Is TNGX or LXRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXRX vs. The Competition

Lexicon Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools